John Pottage Net Worth

John Pottage biography

John C. Pottage Jr., M.D. serves as Independent Director of the Company. Dr. Pottage has served as Senior Vice President and Chief Scientific and Medical Officer of ViiV Healthcare since November 2009. From September 2008 to November 2009, Dr. Pottage served as Senior Vice President, Head of Infectious Disease Medicine Development Center and, from June 2007 to September 2008, as the Vice President, Global Clinical Development of Antivirals, at GlaxoSmithKline. Prior to joining GlaxoSmithKline, Dr. Pottage served as Chief Medical Officer and Senior Vice President of Drug Development of Achillion Pharmaceuticals from May 2002 to May 2007. From July 1998 to May 2002, Dr. Pottage served as Medical Director of Vertex Pharmaceuticals. Pottage’s extensive industry and executive experience, his broad experience within the biopharmaceutical sector and his knowledge of the life sciences industry qualifies him to serve on our Board of Directors.

What is the salary of John Pottage?

As the Independent Director of Spero Therapeutics Inc, the total compensation of John Pottage at Spero Therapeutics Inc is $97,874. There are 10 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.

How old is John Pottage?

John Pottage is 67, he's been the Independent Director of Spero Therapeutics Inc since 2018. There are 2 older and 16 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.

What's John Pottage's mailing address?

John's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Spero Therapeutics Inc

Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela и Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.

What does Spero Therapeutics Inc do?

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.

Spero Therapeutics Inc executives and stock owners

Spero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ankit Mahadevia,
  President, Chief Executive Officer, Director
• Dr. Ankit Mahadevia M.D., MBA,
  Co-Founder, CEO, Pres & Director
• Cristina Larkin,
  Chief Operating Officer and Chief Commercial Officer
• David Melnick,
  Cheif Medical Officer
• Dr. David A. Melnick M.D.,
  Chief Medical Officer
• Cristina Larkin,
  Chief Operating Officer
• Thomas Parr,
  Chief Scientific Officer
• Cynthia Smith,
  Independent Director
• Milind Deshpande,
  Independent Chairman of the Board
• Frank Thomas,
  Independent Director
• Patrick Vink,
  Independent Director
• John Pottage,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Sharon Klahre,
  IR Contact Officer
• Scott Jackson,
  Independent Director
• Timothy Keutzer,
  Chief Development Officer
• Stephen DiPalma,
  Chief Financial Officer, Treasurer
• Timothy Keutzer,
  Chief Devel. Officer
• James P. Brady,
  Chief Human Resource Officer
• David Musselman,
  Sr. VP of Sales & Market Access
• Tamara Lynn Joseph L.L.M., J.D.,
  Chief Legal Officer
• Ted Jenkins,
  VP & Head of Investor Relations
• Dr. Thomas R. Parr Jr., Ph.D.,
  Chief Scientific Officer
• Satyavrat Shukla C.F.A.,
  Chief Financial Officer
• David P Southwell,
  Director
• John J Gorman,
  Director
• Jack Fingerhut,
  President
• Allen S Greene,
  Chairman of the Board and CEO
• Lager H Martin,
  Director
• Joel Sendek,
  Chief Financial Officer
• Plc Gsk,
  10% owner
• Joseph R Fish,
  EVP & Chief Technology Officer
• Leonard J Stanley,
  Director
• Vikas Goyal,
  Director
• Casper Breum,
  Director
• Stanley P Wirtheim,
  Chief Financial Officer
• Zohar Ben Dov,
  10% owner
• Esther Rajavelu,
  See Remarks
• Capital Management, Llc Aqu...,
  
• Kathleen Tregoning,
  
• Kamal Hamed,
  Chief Medical Officer
• Sath Shukla,
  CEO & President
• Tamara L Joseph,
  Chief Legal Officer